INCYTE CORP 8K

Incyte completed its $1.25 billion-plus milestone acquisition of Vega Therapeutics, gaining Phase 3 asset VGA039 for von Willebrand disease and recording the deal as a one-time R&D expense in 2026.

On July 6, 2026, Incyte Corporation announced that it has completed the acquisition of Vega Therapeutics, Inc., a wholly owned subsidiary of Star Therapeutics LLC, for $1.25 billion in upfront consideration plus up to $750 million in additional sales milestone payments, adding the Phase 3 investigational monoclonal antibody VGA039 for von Willebrand disease to Incyte’s hematology portfolio; the company expects to record the upfront payment as a one-time R&D expense in its third quarter and full-year 2026 GAAP and non-GAAP financial results.

Filing Facts

CIK

879169

Ticker

INCY

Form

8K

Source Type

sec

Accession

0000879169-26-000048

Alert Tier

8